Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
William J. Sandborn, Laurent Peyrin‐Biroulet, Daniel Quirk, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 20, Iss. 8, pp. 1821-1830.e3
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 226
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
Francesca Ferretti, Rosanna Cannatelli, Maria Camilla Monico, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2302-2302
Open Access | Times Cited: 71
JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases
Claudia Herrera‐deGuise, X Serra-Ruiz, Ernesto Lastiri, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 47
Blockade of IL-23: What is in the Pipeline?
Tommaso Lorenzo Parigi, Marietta Iacucci, Subrata Ghosh
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. Supplement_2, pp. ii64-ii72
Open Access | Times Cited: 68
Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention
Wenqian Li, Tiantian Zhao, Dacheng Wu, et al.
Current Oncology (2022) Vol. 29, Iss. 9, pp. 6091-6114
Open Access | Times Cited: 56
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, et al.
Gastroenterology (2024) Vol. 167, Iss. 7, pp. 1307-1343
Closed Access | Times Cited: 13
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
David Fudman, Ryan McConnell, Christina Ha, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 454-468
Closed Access | Times Cited: 11
Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis
Soichi Yagi, Hirokazu Fukui, Maiko Ikenouchi, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 1, pp. 217-217
Open Access | Times Cited: 1
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2865-2865
Open Access | Times Cited: 19
Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study
Arshdeep Singh, Vandana Midha, Kirandeep Kaur, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 2, pp. 300-307
Closed Access | Times Cited: 19
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Marcello Imbrizi, Fernando Magro, Cláudio Saddy Rodrigues Coy
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1272-1272
Open Access | Times Cited: 18
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice
Rupa Banerjee, Vishal Sharma, Rajendra Patel, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 22-35
Closed Access | Times Cited: 7
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
Bruce E. Sands, Geert R. D’Haens, Remo Panaccione, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 2084-2095.e4
Open Access | Times Cited: 7
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience
Oren Ledder, Michael T. Dolinger, Marla C. Dubinsky, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 7
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis
Ashwin N. Ananthakrishnan, M. Hassan Murad, Frank I. Scott, et al.
Gastroenterology (2024) Vol. 167, Iss. 7, pp. 1460-1482
Closed Access | Times Cited: 7
Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis
Remo Panaccione, Silvio Danese, Wen Zhou, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 3, pp. 393-408
Open Access | Times Cited: 16
Upfront tofacitinib in patients with biological-naïve ulcerative colitis – An Indian multicentric experience
Suprabhat Giri, Sukanya Bhrugumalla, Abhishek Kamuni, et al.
Indian Journal of Gastroenterology (2023) Vol. 43, Iss. 1, pp. 237-243
Closed Access | Times Cited: 14
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
Ferdinando D’Amico, Fernando Magro, Laurent Peyrin‐Biroulet, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 5, pp. 835-844
Open Access | Times Cited: 30
Review article: guide to tofacitinib dosing in patients with ulcerative colitis
Peter M. Irving, Yvette Leung, Marla C. Dubinsky
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 7, pp. 1131-1145
Open Access | Times Cited: 17
Strategies and opportunities of micro/nano delivery systems for targeted therapy of ulcerative colitis: Focus on underlying mechanisms and future perspectives
Zihan Liu, Han Liu, Jialing Cheng, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 2, pp. 109074-109074
Closed Access | Times Cited: 10
Fabrication of enteric coated mucoadhesive pellets of Tofacitinib citrate for treatment of ulcerative colitis
Purushottam Gangane, Aparna Yadav, Rohini Kharwade, et al.
Particulate Science And Technology (2025), pp. 1-12
Closed Access
A narrative literature review of the incidence and prevalence of safety outcomes in patients with ulcerative colitis
Milena Gianfrancesco, Abiola O. Awofeso, Diogo Branquinho, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Open Access
Arbutin ameliorated ulcerative colitis of mice induced by dextran sodium sulfate (DSS)
Chuan Zhang, Huiping Zhu, Hui Jie, et al.
Bioengineered (2021) Vol. 12, Iss. 2, pp. 11707-11715
Open Access | Times Cited: 21
Dual biological therapy and small molecules in pediatric inflammatory bowel disease
Francesca Penagini, Luisa Lonoce, Luisa Abbattista, et al.
Pharmacological Research (2023) Vol. 196, pp. 106935-106935
Open Access | Times Cited: 9
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Ferdinando D’Amico, Francesca Lusetti, Laurent Peyrin‐Biroulet, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 9, pp. 1425-1432
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top